View Author
patient cancer irinotecan study pharmacokinetic treatment effect transporter sunitinib cyp 3a concentration plasma -38 sn -38 clearance polymorphism imatinib metabolite activity cisplatin group analysis level dosing tamoxifen oncol toxicity genotype platinum sample pharmacol inhibitor exposure table result variant allele metabolism expression value phase interaction cancer patients variability uptake cpt -11 midazolam sn -38g association erythromycin therapy grade protein tumor neutropenia number diarrhea resistance cyp 3a activity -11 factor response ugt 1a verweij j endoxifen transport mathijssen thyroid blood parameter method enzyme erythromycin breath test infusion compound course figure research haplotype verweij
10 Most Recent Publications
|
SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
(Article)
Oudijk, L. Gaal, J. Loon, R.L.E. van O'Sullivan, M.J. Krijger, R.R. de Dinjens, W.N.M. Korpershoek, E. Nederveen, F.H. van Kelly, L. Schiavon, G. Verweij, J. Mathijssen, R.H.J. Bakker, M.A. den Oldenburg, R. |
2013-03-01
|
|
Doubt about the feasibility of preemptive genotyping
(Article)
Koch, B.C.P. Schaik, R.H.N. van Gelder, T. van Mathijssen, R.H.J. |
2013-03-01
|
|
Long-term prospective population PK study in GIST patients - Response
(Article)
Mathijssen, R.H.J. Bruijn, P. de Eechoute, K. Sparreboom, A. |
2013-02-15
|
|
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin
(Article)
Elens, L. Nieuweboer, A.J.M. Clarke, S.J. Charles, K.A. Graan, A-J.M. de Haufroid, V. Mathijssen, R.H.J. Schaik, R.H.N. van |
2013-01-01
|
|
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension
(Article)
Eechoute, K. Veldt, A.A.M. van der Mathijssen, R.H.J. Boven, E. Oosting, R.S. Kappers, M.H.W. Wessels, J.A.M. Gelderblom, H. Guchelaar, H.J. Reyners, A.K.L. Herpen, C.M.L. Haanen, J.B. |
2012-10-01
|
|
Individualization of tamoxifen treatment for breast carcinoma
(Article)
Binkhorst, L. Gelder, T. van Mathijssen, R.H.J. |
2012-10-01
|
|
Reply to F.L. Opdam et al
(Article)
Graan, A-J.M. de Binkhorst, L. Loos, W.J. Schaik, R.H.N. van Verweij, J. Mathijssen, R.H.J. |
2012-02-01
|
|
Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
(Article)
Binkhorst, L. Mathijssen, R.H.J. Ghobadi Moghaddam-Helmantel, I.M. Bruijn, P. de Gelder, T. van Wiemer, E.A.C. Loos, W.J. |
2011-12-15
|
|
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression
(Article)
Kappers, M.H.W. Esch, J.H.M. van Visser, T.J. Smedts, F. Krijger, R.R. de Eechoute, K. Mathijssen, R.H.J. Sleijfer, S. Leijten, F.P.J. Danser, A.H.J. Meiracker, A.H. van den |
2011-10-01
|
|
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
(Article)
Graan, A-J.M. de Teunissen, S.F. Beijnen, J.H. Mathijssen, R.H.J. Vos, F.Y.F.L. de Loos, W.J. Schaik, R.H.N. van Jongh, F.E. de Alphen, R.J. van Holt, B. van der Verweij, J. Seynaeve, C.M. |
2011-08-20
|
